Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
In this educational workshop, Parexel regulatory experts, all former regulators, provide a comprehensive view of anti-drug conjugates (ADCs) for the treatment of cancer - from non-clinical, CMC, and clinical perspectives. In this 90-minute educational session, we explore how ADCs are developed and characterized in the non-clinical stage, the critical considerations, and challenges in manufacturing processes (CMC), and the exciting clinical developments shaping the landscape of cancer therapy. Join us as we delve into the multidimensional aspects of ADCs and their potential to revolutionize cancer treatment.
Related Insights
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Decoding FDA’s new flexible CMC requirements for cell and gene therapies
Jan 26, 2026
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
New Oncology head brings biotech industry and academic research experience
Oct 2, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Related Insights
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Decoding FDA’s new flexible CMC requirements for cell and gene therapies
Jan 26, 2026
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
New Oncology head brings biotech industry and academic research experience
Oct 2, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023